Literature DB >> 11517011

Fibroblast growth factor receptor 1 (FGFR1) is over-expressed in benign prostatic hyperplasia whereas FGFR2-IIIc and FGFR3 are not.

S Boget1, C Cereser, P Parvaz, A Leriche, A Revol.   

Abstract

OBJECTIVE: Benign prostatic hyperplasia (BPH) is one of the major public health problems among men: 50% of men over 55 are concerned with this disease. Prostate growth is under the control of androgens which act by means of several growth factors such as fibroblast growth factors (FGFs), epidermal growth factor and transforming growth factor beta. Basic FGF (bFGF) has been shown to stimulate prostatic stromal growth. In BPH, bFGF concentration is two- to threefold higher than in normal prostate. In this work, the bFGF receptors (FGFR1, FGFR2-IIIc and FGFR3) genes expression was evaluated to study the correlation between the expression of bFGF receptors and induction of BPH.
METHODS: The expression of FGFRs was analyzed by RT-PCR, FGFR1 was localized by immunohistochemistry and protein expression was evaluated by Western blot.
RESULTS: A two- to eightfold over-expression of FGFR1 was observed in BPH compared with normal prostates. FGFR1 was localized in the stroma both in BPH and in normal prostates and 1.5- to 2.5-fold over-expression of the protein was observed. The expression of FGFR2-IIIc and FGFR3, more secondary receptors, was not significantly different between BPH and normal prostates.
CONCLUSIONS: bFGF receptors and particularly FGFR1 seem to be involved in the induction and evolution of BPH and probably potentiate bFGF over-expression effects in BPH.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517011     DOI: 10.1530/eje.0.1450303

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

1.  Analysis of non-canonical fibroblast growth factor receptor 1 (FGFR1) interaction reveals regulatory and activating domains of neurofascin.

Authors:  Katja Kirschbaum; Martin Kriebel; Eva Ursula Kranz; Oliver Pötz; Hansjürgen Volkmer
Journal:  J Biol Chem       Date:  2009-08-07       Impact factor: 5.157

Review 2.  Growth factors in benign prostatic hyperplasia: basic science implications.

Authors:  M Scott Lucia; James R Lambert
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

3.  Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH.

Authors:  Motoaki Saito; Panagiota Tsounapi; Ryo Oikawa; Shogo Shimizu; Masashi Honda; Takehiro Sejima; Yukako Kinoshita; Shuhei Tomita
Journal:  Sci Rep       Date:  2014-01-22       Impact factor: 4.379

4.  Involvement of fibroblast growth factor receptor genes in benign prostate hyperplasia in a Korean population.

Authors:  Hae Jeong Park; Su Kang Kim; Jong Woo Kim; Sang Hyub Lee; Koo Han Yoo; Joo-Ho Chung
Journal:  Dis Markers       Date:  2013-12-09       Impact factor: 3.434

5.  Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).

Authors:  Raquel Frenedoso da Silva; Ellen Nogueira-Pangrazi; Larissa Akemi Kido; Fabio Montico; Sarah Arana; Dileep Kumar; Komal Raina; Rajesh Agarwal; Valéria Helena Alves Cagnon
Journal:  J Biomed Sci       Date:  2017-05-12       Impact factor: 8.410

6.  Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia.

Authors:  Bong Kyun Park; Chang Won Kim; Jeong Eun Kwon; Manorma Negi; Yong Tae Koo; Sang Hun Lee; Dong Hyun Baek; Yoo Hun Noh; Se Chan Kang
Journal:  Pharm Biol       Date:  2019-12       Impact factor: 3.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.